KR950000167A - 항-엔도테린 물질의 서방 제제 - Google Patents

항-엔도테린 물질의 서방 제제 Download PDF

Info

Publication number
KR950000167A
KR950000167A KR1019940014507A KR19940014507A KR950000167A KR 950000167 A KR950000167 A KR 950000167A KR 1019940014507 A KR1019940014507 A KR 1019940014507A KR 19940014507 A KR19940014507 A KR 19940014507A KR 950000167 A KR950000167 A KR 950000167A
Authority
KR
South Korea
Prior art keywords
amino acid
asp
sustained
peptide
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019940014507A
Other languages
English (en)
Korean (ko)
Inventor
야스따까 이가리
히또시 이께다
마사오 쓰다
가즈미찌 야마모또
미쓰히로 와끼마스
Original Assignee
다께다 구니오
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다께다 구니오, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 다께다 구니오
Publication of KR950000167A publication Critical patent/KR950000167A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1019940014507A 1993-06-24 1994-06-23 항-엔도테린 물질의 서방 제제 Withdrawn KR950000167A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15339393 1993-06-24
JP93-153393 1993-06-24

Publications (1)

Publication Number Publication Date
KR950000167A true KR950000167A (ko) 1995-01-03

Family

ID=15561515

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940014507A Withdrawn KR950000167A (ko) 1993-06-24 1994-06-23 항-엔도테린 물질의 서방 제제

Country Status (6)

Country Link
EP (1) EP0647449A1 (enExample)
KR (1) KR950000167A (enExample)
CN (1) CN1109780A (enExample)
CA (1) CA2126619A1 (enExample)
FI (1) FI943071A7 (enExample)
NO (1) NO942396L (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007399A1 (en) * 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
EP0815870A3 (en) * 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Composition for prohylaxis or treatment of cerebral infarction
AU4196697A (en) * 1996-09-16 1998-04-14 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
WO2000025803A1 (en) * 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparations
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
EP1277787A4 (en) * 2000-04-28 2009-11-11 Mitsubishi Tanabe Pharma Corp METHOD FOR PRODUCING MICROSPHERES
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
BRPI0620819A2 (pt) 2005-12-30 2011-11-22 Zensun Shangai Science & Technology Ltd uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69220861T2 (de) * 1991-08-13 1997-11-20 Takeda Chemical Industries Ltd Zyklische Peptide und ihre Verwendung
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.

Also Published As

Publication number Publication date
FI943071L (fi) 1994-12-25
NO942396L (no) 1994-12-27
FI943071A7 (fi) 1994-12-25
CA2126619A1 (en) 1994-12-25
EP0647449A1 (en) 1995-04-12
CN1109780A (zh) 1995-10-11
NO942396D0 (enExample) 1994-06-23
FI943071A0 (fi) 1994-06-23

Similar Documents

Publication Publication Date Title
KR950000167A (ko) 항-엔도테린 물질의 서방 제제
Veber et al. The design of metabolically-stable peptide analogs
US10626146B2 (en) α4β7 thioether peptide dimer antagonists
Jensen et al. Backbone Amide Linker (BAL) strategy for solid-phase synthesis of C-terminal-modified and cyclic peptides1, 2, 3
CN102711789B (zh) 用于降低甲状旁腺激素水平的治疗剂
JP2726647B2 (ja) 環状ペプチドおよびその用途
KR940013530A (ko) 서방성 제제
RU94035760A (ru) Опиоидные пептиды
JP2002530430A (ja) Ｃ型肝炎ウイルスｎｓ３プロテアーゼ阻害用の医薬組成物
FR2465713A1 (fr) Nouveaux peptides biologiquement actifs et leur emploi comme medicaments
JP2997519B2 (ja) ブラジキニンの拮抗作用を有するペプチド
JP3810083B2 (ja) 成長因子の放出を促進し得る２−アルキルトリプトファン含有ペプチド化合物
McGregor et al. Potent analgesic activity of the enkephalin-like tetrapeptide H-Tyr-D-Ala-Gly-Phe-NH2
MXPA97002275A (en) Polypeptidic compounds containing d-2 alkyltriptophan capable of promoting the hormone release of growth
JP2000502089A (ja) 成長ホルモンの放出を促進できるｄ―２―アルキルトリプトファンを含有するオリゴペプチド化合物
WO2023214509A1 (ja) 界面活性剤と併用するためのペプチド化合物を含む組成物
US5872100A (en) Peptides containing D-2-Alkyl-Tryptophan
Ballet et al. Blood− brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility
EP0646601B1 (en) Motilin-like polypeptides with gastrointestinal motor stimulating activity
US4559324A (en) Polypeptide-diesters, their production and use
Eaton et al. Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-β receptor and possess cellular activity
EP0842193B1 (en) Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone
US5807985A (en) Oligopeptide compounds containing D-2-alkyltryptophan capable of promoting the release of growth hormone
US4127532A (en) Novel heptapeptides, intermediates therefor, and compositions and methods employing said heptapeptides
KR20070083815A (ko) 고체상 합성에서 ｓ-알킬-술페닐 보호기

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000